From The New York Times:
Buoyed by positive results in its earlier studies, Johnson & Johnson has begun the final stage of clinical trials for its coronavirus vaccine.
Although they started a couple of months behind the other so-called Phase 3 trials in the United States, Johnson & Johnson’s trials, which began on Monday, will be the largest, with plans to enroll 60,000 participants. And this experimental vaccine may have considerable advantages over some of its competitors, experts said. It does not need to be stored in subzero temperatures, and may require just one dose instead of two.
From the Population Research Institute:
Janssen, the pharmaceutical division of consumer product giant Johnson & Johnson, is using the human fetal cell line PER.C6 to develop its vaccine. The PER.C6 fetal cell line was derived from retinal tissue taken from an 18-week-old baby boy who was aborted in the Netherlands in 1985 and later converted into a fetal cell line in 1995.